Clinical trial NCT06743386: Pilot Study of EUS-Guided Radiofrequency and FOLFIRINOX in Advanced Pancreatic Cancer (RadioFAP )
Official title: Pilot Study Evaluating the Combination of Endoscopic Ultrasound-Guided Radiofrequency and FOLFIRINOX in Locally Advanced Pancreatic Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Pancreatic Adenocarcinoma
Keywords: EUS-Guided Radiofrequency Ablation (RFA)
Pancreatic Tumor Ablation
Minimally Invasive Tumor Treatment
Lead sponsor: French Society of Digestive Endoscopy
Sponsor class: OTHER
First posted: 2024-12-19
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Pancreatic adenocarcinoma (PDAC) constitutes 90% of pancreatic tumors and is projected to become the second leading cause of cancer-related mortality in Europe by 2030. In France, its incidence doubled in men and tripled in women between 1982 and 2012. PDAC remains the digestive cancer with the poorest prognosis, with a five-year overall survival rate below 10% across all stages. Only surgical management with R0 resection (surgical margins free of cancer cells) offers a chance for cure or prolonged survival. However, surgery is feasible in only 15% of patients, as the disease is typically diagnosed at a late stage-locally advanced in 35% of cases or metastatic in 50%. Chemotherapy, specifically FOLFIRINOX, is the standard treatment for advanced cases, but resistance to chemotherapy poses a significant challenge. A key contributor to this resistance is the tumor stroma, which constitutes most of the tumor mass. This fibrous tissue acts as a mechanical barrier, restricting blood flow and potentially limiting the delivery of chemotherapy to cancer cells. The development of endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) has shown promise in treating pancreatic neuroendocrine tumors (pNETs) and pancreatic cystic neoplasms, sparking interest in its potential for PDAC. Preliminary studies demonstrate the feasibility of radiofrequency in PDAC, showing increased blood flow around treated sites. Combining systemic chemotherapy with radiofrequency may enhance drug diffusion and improve treatment efficacy. Additionally, tumor thermoablation could stimulate an immune response, as observed in experimental and clinical research. This study aims to evaluate the feasibility of tumor destruction via radiofrequency ablation combined with FOLFIRINOX in improving progression-free survival for patients with PDAC.


Eligibility criteria: Inclusion Criteria:

1. Patients over the age of 18
2. Patients with locally advanced, borderline resectable, or inoperable pancreatic adenocarcinoma, confirmed by histological or cytological tests and assessed through a multidisciplinary consultation.
3. Patients without evidence of metastases.
4. No prior anti-tumoral treatment.
5. World Health Organization (WHO) performance status ≤ 1.
6. Measurable tumor according to the RECIST v1.1 criteria: a tumor lesion with the largest diameter ≥ 20 mm using conventional imaging techniques or ≥ 10 mm using spiral CT scan.
7. Patient who has provided written consent.
8. Patient with no contraindications to general anesthesia.
9. Pancreatic tumor accessible via endoscopic ultrasound.
10. Patient enrolled in a social security program (beneficiary or dependent).

Exclusion Criteria:

* 1. Other types of non-ductal or solid pancreatic tumors, including endocrine tumors, acinar cell adenocarcinoma, cystadenocarcinoma, and malignant ampullary tumors.

  2. Presence of metastases. 3. Contraindication to treatment with 5FU, oxaliplatin, or irinotecan. 4. Patients with a tumor that could benefit from neoadjuvant treatment with radiochemotherapy or chemotherapy alone for secondary resection (decision by a multidisciplinary committee).

  5. Pre-existing neuropathy, Gilbert's disease, or known UGT1A1\*28/\*28 genotype. 6. Chronic inflammatory bowel disease. 7. Other concurrent cancers, or a history of cancer within the last 5 years, except for in situ cervical cancer that has been treated or a properly treated basal cell carcinoma or squamous cell carcinoma.

  8. Hereditary intolerance to fructose. 9. Individuals deprived of liberty or under guardianship. 10. Inability to follow up with the study due to geographical, social, or psychological reasons.

  11. Contraindication to echo-endoscopy-guided cytopuncture (coagulation disorders or previously operated stomach).

  12. Neutrophil count \< 1500/mm³. 13. Platelet count \< 70,000/mm³. 14. Patients are not effectively treated for neoplastic jaundice if present at diagnosis.

  15. Patient in an exclusion period or currently participating in another clinical research protocol.

  16. Patients are unable to understand or read the information/consent form. 17. Pregnant women or those wishing to become pregnant during the study period, or breastfeeding women.

  18. Patients with implanted pacemakers or implantable cardioverter-defibrillators (ICDs).

Primary outcomes:
measure: The success rate of tumor destruction achieved using radiofrequency ablation (RFA) with a radiofrequency needle guided by endoscopic ultrasound (EUS), in combination with chemotherapy.
timeFrame: 2, 6, 9, 12, and18 months
Secondary outcomes:
measure: Progression-Free Survival:
timeFrame: 2, 6, 9, 12, and18 months
measure: Impact of radiofrequency tumor ablation combined with FOLFIRINOX on overall survival
timeFrame: 2, 6, 9, 12, and18 months
measure: Impact of radiofrequency tumor ablation with FOLFIRINOX on quality of life
timeFrame: 2, 6, 9, 12, and 18 months
measure: Effect of radiofrequency ablation combined with FOLFIRINOX on secondary resectability
timeFrame: 2, 6, 9, 12, and18 months
measure: Pancreatic intratumoral radiofrequency technical success
timeFrame: 14 days before chemotherapy and at 2 and 4 months post-treatment.
measure: RFA tolerance
timeFrame: 14 days before chemotherapy and at 2 and 4 months post-treatment.
Other outcomes:
Locations:
Study officials:
References: